Healthy HCV market kills Merck's breakthrough status
This article was originally published in Scrip
Executive Summary
The FDA notified Merck late last month that regulators were rescinding the breakthrough therapy designation the agency had granted for the firm's hepatitis C virus combination product grazoprevir/elbasvir (MK-5172/MK-8742), citing the availability of other recently approved treatments for genotype 1 patients, the company revealed on 4 February.